These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 11825311)
21. Tolterodine: an overview. Wefer J; Truss MC; Jonas U World J Urol; 2001 Nov; 19(5):312-8. PubMed ID: 11760779 [TBL] [Abstract][Full Text] [Related]
22. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476 [TBL] [Abstract][Full Text] [Related]
23. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103 [TBL] [Abstract][Full Text] [Related]
24. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. Malone-Lee J; Shaffu B; Anand C; Powell C J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895 [TBL] [Abstract][Full Text] [Related]
25. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Sussman D; Garely A Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616 [TBL] [Abstract][Full Text] [Related]
26. Comparison of fesoterodine and tolterodine in patients with overactive bladder. Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298 [TBL] [Abstract][Full Text] [Related]
27. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: a review. Rovner ES; Wein AJ Eur Urol; 2002 Jan; 41(1):6-14. PubMed ID: 11999467 [TBL] [Abstract][Full Text] [Related]
28. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Getsios D; Caro JJ; Ishak KJ; El-Hadi W; Payne K Clin Ther; 2004 Mar; 26(3):431-8. PubMed ID: 15110136 [TBL] [Abstract][Full Text] [Related]
29. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder. Swift S; Garely A; Dimpfl T; Payne C; Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517 [TBL] [Abstract][Full Text] [Related]
30. Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Freeman R; Hill S; Millard R; Slack M; Sutherst J; Obstet Gynecol; 2003 Sep; 102(3):605-11. PubMed ID: 12962951 [TBL] [Abstract][Full Text] [Related]
31. Tolterodine: a clinical review. Crandall C J Womens Health Gend Based Med; 2001 Oct; 10(8):735-43. PubMed ID: 11703885 [TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Appell RA Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844 [TBL] [Abstract][Full Text] [Related]
34. Tolterodine once-daily in treatment of the overactive bladder. Peters KM; Huang RR Urology; 2001 Nov; 58(5):829-32. PubMed ID: 11711378 [No Abstract] [Full Text] [Related]
35. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Diokno AC; Appell RA; Sand PK; Dmochowski RR; Gburek BM; Klimberg IW; Kell SH; Mayo Clin Proc; 2003 Jun; 78(6):687-95. PubMed ID: 12934777 [TBL] [Abstract][Full Text] [Related]
36. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Guay DR Pharmacotherapy; 1999 Mar; 19(3):267-80. PubMed ID: 10221366 [TBL] [Abstract][Full Text] [Related]
37. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. D'Souza AO; Smith MJ; Miller LA; Doyle J; Ariely R J Manag Care Pharm; 2008 Apr; 14(3):291-301. PubMed ID: 18439051 [TBL] [Abstract][Full Text] [Related]